Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment

Inclusion Criteria: * Age range: 18-75 years old (including 18 and 75 years old), regardless of gender. * Individuals with chronic hepatitis B liver fibrosis or cirrhosis. * According to the "Diagnosis and Treatment Guidelines for Primary Liver Cancer" (2024 edition) liver cancer diagnosis roadmap, the first clinical diagnosis is Hepatocellular carcinoma(HCC). * The staging of liver cancer is CNLC stage Ia - IIa. * Radical treatment has been completed, with surgical resection or local ablation. * 8-12 weeks after radical surgery, imaging and serological evaluations showed no residual cancerous lesions and no new cancerous lesions were found. * Child Pugh score A/B. * Voluntarily joining the group, able to understand and sign an informed consent form. Exclusion Criteria: * Pregnant and lactating women; * Prior to radical liver cancer surgery, the patient had received radiation, chemotherapy, molecular targeting, immunotherapy, and other anti-tumor treatments; * Receive other anti-tumor Chinese medicine (including traditional Chinese patent medicines and simple preparations or Chinese herbal medicine); * Individuals with mental illnesses, especially those with a history of depression, anxiety, mania, schizophrenia, or a family history of mental illness (especially those with a history of depression or tendencies towards depression); * Combination of hepatitis A, C, D, E, and/or current HIV infections; * Kidney diseases: acute and chronic nephritis, renal insufficiency, nephrotic syndrome, etc., or screening with blood creatinine\>2.0 × ULN; * Autoimmune diseases, including psoriasis, systemic lupus erythematosus, autoimmune liver disease, etc; * Patients who experience upper gastrointestinal bleeding within the first 3 months (including the screening period) prior to screening; * Individuals with a serious history of heart disease, especially those with unstable or poorly controlled heart disease within the past 6 months; * Individuals who plan to receive organ transplantation or have already undergone organ transplantation; * Those who are allergic to Compound Biejia Ruangan Tablets, nucleoside (acid) analogues, or drug excipients, or who meet any contraindications in the experimental drug instructions; * Have used other anti fibrotic drugs within the first 6 months of enrollment, such as Fuzheng Huayu, Anluo Huaxian, and Ganshuang Granules. * Other situations where the participant has participated in other intervention trials within the previous month or where the researcher deems it unsuitable for inclusion.